Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the evaluation of the efficacy of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) in HER2-positive metastatic breast cancer in the DESTINY-Breast01 trial.
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]
